Aladzsity I, Kovács M, Semsei A, Falus A, Szilágyi A, Karádi I, Varga G, Füst G, Várkonyi J
3rd Department of Internal Medicine, Semmelweis University, 1125 Budapest, Hungary.
Leuk Res. 2009 Nov;33(11):1570-3. doi: 10.1016/j.leukres.2009.03.009. Epub 2009 Apr 29.
The serum levels of interleukin 6 (IL6) are known to be elevated in two diseases of the elderly age, myelodysplastic syndrome (MDS) and multiple myeloma (MM). Authors suppose that one of the possible causes of this elevation could be a difference between these patients and healthy subjects in the frequency of polymorphic variants of the genes regulating IL6 levels. Scarce and contradictory comparative data are available for MM and to our best knowledge this is the first study on IL6 promoter and IL6 receptor (IL6R) polymorphism in MDS. Therefore we determined the Asp358Ala polymorphism of the IL6 receptor gene and the -174 G>C promoter polymorphism of the IL6 gene in blood samples of 102 MDS and 100 MM patients and 99 age- and sex-matched hospitalized controls had been tested for this purpose as well. There was no significant difference between patients with either disease and controls regarding IL6 promoter/L-6R. Authors therefore assume other mechanisms causing high IL6 levels are not related to either of these polymorphisms. Moreover authors consider important to propose a hypothesis how elements of signal transduction in iron metabolism might be involved in the development of MM and MDS in elderly age.
已知在老年的两种疾病——骨髓增生异常综合征(MDS)和多发性骨髓瘤(MM)中,白细胞介素6(IL6)的血清水平会升高。作者推测,这种升高的可能原因之一可能是这些患者与健康受试者在调节IL6水平的基因多态性变体频率上存在差异。关于MM的比较数据稀少且相互矛盾,据我们所知,这是第一项关于MDS中IL6启动子和IL6受体(IL6R)多态性的研究。因此,我们测定了102例MDS患者、100例MM患者血样中IL6受体基因的Asp358Ala多态性以及IL6基因的 -174 G>C启动子多态性,并且还为此检测了99名年龄和性别匹配的住院对照者。在IL6启动子/L-6R方面,患有这两种疾病的患者与对照者之间没有显著差异。因此,作者认为导致IL6水平升高的其他机制与这些多态性均无关。此外,作者认为提出一个关于铁代谢信号转导元件可能如何参与老年MM和MDS发生发展的假说是很重要的。